New York S 3104: Prohibits the sale and distribution of synthetic cannabinoids; and establishes a statewide synthetic cannabinoid surrender program

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S03104 Summary:

BILL NOS03104 

&nbsp

SAME ASSAME AS A04211

&nbsp

SPONSORCOONEY

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Amd §365-a, Soc Serv L; amd §§3216, 3221 & 4303, Ins L

&nbsp

Requires comprehensive coverage for treatment of obesity, including coverage for prevention and wellness, nutrition counseling, intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medication.

Go to top S03104 Actions:

BILL NOS03104 

&nbsp

01/23/2025REFERRED TO HEALTH

01/07/2026REFERRED TO HEALTH

Go to topS03104 Committee&nbspVotes:

Go to topS03104 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS03104 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 3104

 2025-2026 Regular Sessions

 IN SENATE

 January 23, 2025
 ___________

 Introduced by Sen. COONEY -- read twice and ordered printed, and when
 printed to be committed to the Committee on Health

 AN ACT to amend the social services law and the insurance law, in
 relation to requiring comprehensive coverage for treatment of obesity

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Subdivision 2 of section 365-a of the social services law
 2 is amended by adding a new paragraph (nn) to read as follows:
 3 (nn) (i) Comprehensive coverage for treatment of obesity, which shall
 4 include coverage for prevention and wellness, nutrition counseling,
 5 intensive behavioral therapy, bariatric surgery, and FDA-approved anti-
 6 obesity medication. For purposes of this paragraph, "FDA-approved anti-
 7 obesity medication" shall mean any medication approved by the federal
 8 food and drug administration with an indication for chronic weight
 9 management in patients with obesity.
 10 (ii) Coverage criteria for FDA-approved anti-obesity medications
 11 provided under this paragraph shall not be more restrictive than the
 12 FDA-approved indications for such treatments.
 13 (iii) Coverage under this paragraph shall be neither different nor
 14 separate from coverage for any other illness, condition, or disorder for
 15 purposes of determining deductibles, lifetime dollar limits, copayment
 16 and coinsurance factors, and benefit year maximum for deductibles and
 17 copayment and coinsurance factors.
 18 (iv) Nothing shall preclude the undertaking of utilization management
 19 to determine the medical necessity for treatment of obesity under this
 20 paragraph, provided that all such appropriateness and medical necessity
 21 determinations are made in the same manner as those determinations are
 22 made for the treatment of any other illness, condition, or disorder
 23 covered by such policy, contract, or plan.
 24 (v) The department shall provide notice to eligible persons regarding
 25 the coverage required by this paragraph. The notice shall be in writing

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD02785-01-5

 S. 3104 2

 1 and shall be prominently positioned in any literature or correspondence
 2 sent to members and shall be transmitted to members within the calendar
 3 year when annual information is made available to eligible persons, or
 4 in any other mailing or communication to eligible persons.
 5 § 2. Subsection (i) of section 3216 of the insurance law is amended by
 6 adding a new paragraph 40 to read as follows:
 7 (40) (A) Every policy which provides medical, major medical, or simi-
 8 lar comprehensive-type coverage shall provide comprehensive coverage for
 9 treatment of obesity, which shall include coverage for prevention and
 10 wellness, nutrition counseling, intensive behavioral therapy, bariatric
 11 surgery, and FDA-approved anti-obesity medication. For purposes of this
 12 paragraph, "FDA-approved anti-obesity medication" shall mean any medica-
 13 tion approved by the federal food and drug administration with an indi-
 14 cation for chronic weight management in patients with obesity.
 15 (B) Coverage criteria for FDA-approved anti-obesity medications
 16 provided under this paragraph shall not be more restrictive than the
 17 FDA-approved indications for those treatments.
 18 (C) Coverage under this paragraph shall neither be different nor sepa-